Provided herein are amino-benzoisothiazole and benzoisothiadiazole amide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, retinal diseases such as acute macular degeneration (AMD) and diabetic macular edema (DME), diseases and conditions characterized by inflammatory processes, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. Also provided are compositions (e.g., pharmaceutical compositions) comprising the compounds provided herein.

The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.

The present application discloses a compound, a display panel and a display device. The compound has the structure shown in Formula 1. The compound of the present application can improve the light extraction efficiency and luminous efficiency, especially the external quantum efficiency of a device, and can also effectively reduce the color shift of the device at multi-angle display.

##STR00001##

The present application discloses a compound, a display panel and a display device. The compound has the structure shown in Formula 1. The compound of the present application can improve the light extraction efficiency and luminous efficiency, especially the external quantum efficiency of a device, and can also effectively reduce the color shift of the device at multi-angle display.

##STR00001##

Disclosed is a compound of formula (I): ##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Disclosed is a compound of formula (I): ##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

A near-infrared absorber includes a compound represented by Chemical Formula 1. A near-infrared absorbing/blocking film, a photoelectric device, an organic sensor, and an electronic device may include the near-infrared absorber.

##STR00001##

In Chemical Formula 1, Ar.sup.1, Ar.sup.2, X.sup.1, L.sup.1, L.sup.2, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same as defined in the detailed description.

The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.

The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.

The present invention relates to an optical sensing element for detection of a narcotic, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, wherein emission of the fluorescent sensing compound is quenched in the presence of the narcotic, and wherein the fluorescent sensing compound is non-polymeric and comprises an electron donor moiety, an electron acceptor moiety and a moiety that influences solubility of the compound in a solvent. Sensing devices incorporating the sensing element and methods of detecting narcotics are also described.